Resistance to First-line Osimertinib in EGFR-mutant NSCLC: Tissue is the Issue

Overview

Journal Clin Cancer Res

Specialty Oncology

Date 2020 Mar 29

PMID 32217611

Citations 7

Authors

Zofia Piotrowska

Aaron N Hata

Affiliations

Soon will be listed here.

Abstract

Matched pre-/posttreatment tissue biopsies from patients with -mutant non-small cell lung cancer demonstrate that histologic transformations, including both small-cell carcinoma and squamous transformation, are unexpectedly common among patients progressing on first-line osimertinib. The study highlights the key role of tissue testing and underscores the need for innovative therapeutic approaches to prevent, rather than treat, resistance..

Citing Articles

Apatinib has anti-tumor effects and induces autophagy in lung cancer cells with high expression of VEGFR-2.

Liu M, Li H Iran J Basic Med Sci. 2024; 27(11):1370-1379.

PMID: 39386238 PMC: 11459337. DOI: 10.22038/ijbms.2024.74820.16246.

Natural History and Real-World Treatment Outcomes for Patients With NSCLC Having Exon 20 Insertion Mutation: An International Association for the Study of Lung Cancer-American Society of Clinical Oncology CancerLinQ Study.

Behera M, Jiang R, Huang Z, Bunn B, Wynes M, Switchenko J JTO Clin Res Rep. 2024; 5(6):100592.

PMID: 38827378 PMC: 11143895. DOI: 10.1016/j.jtocrr.2023.100592.

Osimertinib in Patients With Treatment-Naive EGFR-Mutant Non-small Cell Lung Cancer: Overall Survival, Post-progression Management and Budget Impact Analysis in Real-World.

Pasello G, Lorenzi M, Scattolin D, Del Conte A, Cecere F, Pavan A Oncologist. 2024; 29(7):596-608.

PMID: 38520745 PMC: 11224988. DOI: 10.1093/oncolo/oyae043.

Molecular Mechanism of EGFR-TKI Resistance in -Mutated Non-Small Cell Lung Cancer: Application to Biological Diagnostic and Monitoring.

Reita D, Pabst L, Pencreach E, Guerin E, Dano L, Rimelen V Cancers (Basel). 2021; 13(19).

PMID: 34638411 PMC: 8507869. DOI: 10.3390/cancers13194926.

Treating disease progression with osimertinib in EGFR-mutated non-small-cell lung cancer: novel targeted agents and combination strategies.

Di Noia V, DAveni A, DArgento E, Rossi S, Ghirardelli P, Bortolotti L ESMO Open. 2021; 6(6):100280.

PMID: 34634633 PMC: 8506968. DOI: 10.1016/j.esmoop.2021.100280.